Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 8/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.71 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.35 |
| ▸ | KCND2 | Q9NZV8 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624922 | 1.00 | KCNA5 (0.71) | KCNA5SCN5ACYP2A13ALDH1A1TSHR | |
| SCHEMBL3584661 | 1.00 | KCNA5 (0.71) | KCNA5SCN5ACYP2A13ALDH1A1TSHR | |
| SCHEMBL1762216 | 1.00 | KCNA5 (0.71) | KCNA5SCN5ACYP2A13ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL909033 | 0.99 | KCNA5 (0.70) | KCNA5SCN5ACYP2A13ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL909031 | 0.99 | KCNA5 (0.70) | KCNA5SCN5ACYP2A13ALDH1A1TSHR | |
| SCHEMBL14434183 | 0.85 | KCNA5 (0.71) | KCNA5SCN5ACYP2A13SLC6A4SLC18A3 | |
| SCHEMBL12810312 | 0.85 | KCNA5 (0.71) | KCNA5SCN5ASLC6A4SLC18A3KCND2 | |
| SCHEMBL12391697 | 0.83 | KCNA5 (1.00) | KCNA5SCN5AL3MBTL1KDM4ESLC6A4 | |
| SCHEMBL2624914 | 0.83 | KCNA5 (1.00) | KCNA5SCN5AL3MBTL1KDM4ESLC6A4 | |
| SCHEMBL6807137 | 0.83 | KCNA5 (1.00) | KCNA5SCN5AL3MBTL1KDM4ESLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-02-04 | — | — | US | claimed |
| US-7534790-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2009-05-19 | — | — | US | claimed |
| US-20080070911-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-03-20 | — | — | US | claimed |
| US-20070004718-A1 | Ion channel modulating compounds and uses thereof | CARDIOME PHAMA CORP. (CA) | 2007-01-04 | — | — | US | claimed |
| US-7101877-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2006-09-05 | — | — | US | claimed |
| US-20050192208-A2 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-09-01 | — | — | US | claimed |
| US-20050020481-A1 | Ion channel modulating compounds and uses thereof | BAIN ALLAN I (CA) | 2005-01-27 | — | — | US | claimed |
| EP-1422217-A2 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2004-05-26 | — | — | EP | claimed |
| EP-1087934-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC (CA) | 2004-02-25 | — | — | EP | claimed |
| EP-1087934-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Nortran Pharmaceuticals Inc. (CA) | 2001-04-04 | — | — | EP | claimed |
| WO-1999050225-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC. (CA) | 1999-10-07 | — | — | WO | claimed |
| US-20160089361-A1 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA | CARDIOME PHARMA CORP (CA) | 2016-03-31 | — | — | US | disclosed |
| US-20150099788-A1 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA | CARDIOME PHARMA CORP (CA) | 2015-04-09 | — | — | US | disclosed |
| EP-2468278-A1 | Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia | Cardiome Pharma Corp. (CA) | 2012-06-27 | — | — | EP | disclosed |
| EP-2462933-A1 | Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia | Cardiome Pharma Corp. (CA) | 2012-06-13 | — | — | EP | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
| EP-1422217-A2 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2004-05-26 | — | — | EP | disclosed |
| EP-1087934-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC (CA) | 2004-02-25 | — | — | EP | disclosed |
| EP-1087934-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Nortran Pharmaceuticals Inc. (CA) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999050225-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC. (CA) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099788-A1 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA | CYP2D6, KCNA6, CYP2A6 | KCNA5 31/4885SCN5A 69/4885CYP2A13 117/4885 |
| US-20050020481-A1 | Ion channel modulating compounds and uses thereof | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885CYP2A13 2875/4885 |
| US-20070004718-A1 | Ion channel modulating compounds and uses thereof | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885CYP2A13 2875/4885 |
| US-20080070911-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885CYP2A13 2875/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885CYP2A13 798/4885 |
| US-20160089361-A1 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA | CYP2D6, KCNA6, CYP2A6 | KCNA5 31/4885SCN5A 69/4885CYP2A13 117/4885 |
| US-20050192208-A2 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 21/4885SCN5A 46/4885CYP2A13 3116/4885 |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885CYP2A13 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.